Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNMBiotechnology
Healthcare
$9.24 -3.20%
-$0.39 today
- Market cap
- $326.66M
- Beta
- 0.89
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$1.57
52W Low $3.69High $16.33
Volume 0.20M
Average 0.26M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$68.06M
FY 2025 · Annual
Net Income
-$59.98M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 50M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 258K | 0 |
| Gross Profit | 0 | 0 | 50M | (258K) | 0 |
| Gross Margin | — | — | 100.0% | — | — |
| Research & Development | 22.36M | 16.89M | 27.6M | 38.16M | 51.52M |
| Selling, General & Admin | 6.29M | 5.83M | 6.32M | 12.47M | 16.54M |
| Operating Expenses | 28.65M | 22.72M | 66.08M | 50.64M | 68.06M |
| Depreciation & Amortization | 325K | 329K | 195K | 258K | 323K |
| EBITDA | (28.34M) | (23.54M) | 23.57M | (42M) | (59.66M) |
| EBITDA Margin | — | — | 47.1% | — | — |
| Operating Income | (28.65M) | (22.72M) | (16.08M) | (50.89M) | (68.06M) |
| Operating Margin | — | — | -32.2% | — | — |
| Interest Income | 77K | 761K | 4.61M | 8.91M | 8.25M |
| Interest Expense | 332K | 388K | 208K | 0 | 0 |
| Other Income / Expenses | (354K) | (1.53M) | 39.25M | 8.64M | 8.08M |
| Income Before Tax | (29M) | (24.25M) | 23.17M | (42.26M) | (59.98M) |
| Pre-Tax Margin | — | — | 46.3% | — | — |
| Income Tax Expense | 0 | 0 | 450K | 0 | 0 |
| Net Income | (29M) | (24.25M) | 22.72M | (42.26M) | (59.98M) |
| Net Margin | — | — | 45.4% | — | — |
| EPS (Basic) | (1.15) | (0.97) | 0.13 | (1.63) | (2.17) |
| EPS (Diluted) | (1.15) | (0.97) | 0.13 | (1.63) | (2.17) |
| 25.13M | 25.13M | 25.13M | 25.85M | 27.7M | |
| 25.13M | 25.13M | 25.13M | 25.85M | 27.7M |
CTNM Earnings Waterfall · TTM
NASDAQ:CTNM · Revenue to Net Income
Key Ratios
EPS$-1.95
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.6
P/S Ratio0.0
Analysis
$0 of revenue converted into -$58.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.95, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| SC 13G | SC 13G filing | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 3, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| SC 13G | SC 13G filing | Oct 28, 2026 |
How much revenue does CTNM generate?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported $0.00 of revenue in fiscal 2025.
Is CTNM profitable?
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) reported -$59.98M of net income.
Continue the stock analysis
Jump to another research area for this company.